drugset / Trial / NCT07522879

A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma

NCT07522879

Phase 2 Recruiting 40 enrolled Eye & ENT Hospital of Fudan University
NaSingle-groupOpen-labelTreatment

Summary

This prospective, multicenter clinical study aims to evaluate the efficacy and safety of neoadjuvant therapy with MRG003 (Becotatug vedotin) combined with epirubicin in patients with EGFR-positive, unresectable recurrent sinonasal adenoid cystic carcinoma (SNACC). The primary question is whether this combination can achieve a sufficient objective response rate (ORR) to enable subsequent radical surgery or improve disease control.

Timeline

Start
2026-05-01
Primary completion
2028-10-01
Completion
2030-07-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Becotatug Vedotin Monoclonal antibody 2 mg/kg Intravenous